Biomechanical Properties of Human Coronary Sinus for Minimally Invasive Mitral Valve Repair

2010 ◽  
Author(s):  
Thuy Pham ◽  
Wei Sun
Keyword(s):  
Mitral Valve ◽  
Mitral Regurgitation ◽  
Mitral Valve Repair ◽  
Operative Mortality ◽  
Treatment Options ◽  
Mitral Valve Regurgitation ◽  
Biomechanical Properties ◽  
Current Treatment ◽  
Valve Repair ◽  
Surgical Treatments

Mitral valve regurgitation, the leakage of blood back to the left atrium during systole, is a significant cause of morbidity and mortality. The current treatment options for symptomatic mitral regurgitation are mitral valve repair and replacement. However, the operative mortality for both of these treatments remains substantial (1). Furthermore, these treatments are often not referred for elderly patients with comorbidities. Thus, there is a pressing need for less invasive, non-surgical treatments of mitral regurgitation.

Determining the Mechanical Properties of Coronary Sinus for Percutaneous Mitral Valve Repair

2008 ◽  
Author(s):  
Thuy M. Pham ◽  
Xuan H. Nguyen ◽  
Milton DeHerrera ◽  
Wei Sun
Keyword(s):  
Mitral Valve ◽  
Mitral Regurgitation ◽  
Mitral Valve Repair ◽  
Operative Mortality ◽  
Treatment Options ◽  
Mitral Valve Regurgitation ◽  
Current Treatment ◽  
Valve Repair ◽  
Percutaneous Mitral Valve Repair ◽  
Surgical Treatments

Mitral valve regurgitation, the leakage of blood back to the left atrium during systole, is a significant cause of morbidity and mortality. The current treatment options for symptomatic mitral regurgitation are mitral valve replacement and mitral valve repair. However, the operative mortality for both of these treatments remains substantial[1]. Furthermore, these treatments are often not referred for elderly patients with comorbidities. Thus, there is a pressing need for less invasive, non-surgical treatments of mitral regurgitation.

Early and Mid-term Results of Mitral Valve Repair in Patients with Degenerative Mitral Regurgitation

2021 ◽  
Author(s):  
Hasan Erdem ◽  
Emre Selçuk
Keyword(s):  
Mitral Valve ◽  
Mitral Regurgitation ◽  
Mitral Valve Repair ◽  
Survival Rates ◽  
Mitral Valve Regurgitation ◽  
Valve Repair ◽  
Repair Rate ◽  
Mitral Repair ◽  
Mid Term Results

Objectives: In this study, we present the mid-term results of patients who underwent valve repair due to degenerative mitral valve regurgitation in the first five years of our mitral valve repair program. Patients and Methods: In this retrospective study, all patients who were operated for degenerative mitral regurgitation by a single surgical team between 2013 and 2017 were investigated. We determined early and mid-term cumulative survival rates, repair failure and freedom from reoperation. In addition, as a specific subgroup, the results of patients under 18 years of age after mitral valve repair were investigated Results: Mitral repair was performed in 121 of 153 degenerative mitral regurgitation patients during the study period. The overall repair rate was 79%. Mitral valve repair rate increased significantly over years. The Median follow-up time was 63 (range 10-92) months. Early mortality was 2.5% (n=3 patients). During the follow-up period, moderate-to-severe mitral regurgitation was observed in 14 (11.8%) patients, mitral valve reoperation was required in 7 (5.9%) patients. Valve repair was performed in 4 of 7 patients under the age of 18. There was no pediatric case requiring reoperation during the follow-up period (median 46 months). Conclusion: Mid-term results of mitral valve repair in degenerative mitral valve patients are satisfactory. The success rate of repair increases in line with surgical experience.

Comparison of Outcomes following Mitral Valve Repair versus Replacement for Chronic Ischemic Mitral Regurgitation: A Meta-Analysis

2016 ◽  
Vol 65 (06) ◽  
pp. 432-441 ◽  
Author(s):  
Deng Yun-dan ◽  
Du Wen-jing ◽  
Xiao Xi-jun
Keyword(s):  
Mitral Valve ◽  
Mitral Regurgitation ◽  
Valve Replacement ◽  
Mitral Valve Repair ◽  
Operative Mortality ◽  
Meta Analysis ◽  
Ischemic Mitral Regurgitation ◽  
Valve Repair ◽  
High Quality ◽  
Chronic Ischemic Mitral Regurgitation

Background The selection of mitral valve surgery, including mitral valve repair and mitral valve replacement, is still an important dilemma for patients with chronic ischemic mitral regurgitation. We carry out a meta-analysis to evaluate the effectiveness and safety of mitral valve repair versus replacement for ischemic mitral regurgitation. Methods We searched PubMed, Embase, the Cochrane Library, and Web of Science to identify studies from their inception to July 2015. A meta-analysis was performed using RevMan 5.3 software (Cochrane Collaboration, Oxford, United Kingdom). A random-effect model was used and sensitivity analysis was performed on studies reporting on operation after 2000, high-quality studies, and those studies reporting on more than 150 patients. Result A total of 2,324 patients were identified from 10 retrospective studies. Mitral valve repair was associated with a trend toward lower operative mortality (odds ratio [OR] = 0.45; 95% confidence interval [CI]: 0.31–0.65; p < 0.0001) and higher recurrence of mitral regurgitation (OR = 5.89; 95% CI: 3.34–10.39; p < 0.00001). Five-year survival rate was similar between the two groups (OR = 1.20; 95% CI: 0.88–1.65; p = 0.25). No differences in reoperation, the incidence of acute renal failure and acute respiratory failure, the length of ICU stay, and the length of hospital stay were found. Conclusion Mitral valve repair was associated with lower operative mortality but a higher recurrence of mitral regurgitation compared with mitral valve replacement. Owing to the limited quantity and quality of the included studies, this conclusion still needs to be further confirmed by conducting more high-quality, multicenter randomized controlled trials with large sample size.

Successful MitraClipTM implantation in a 15-year-old patient with multiple prior cardiac surgeries

2012 ◽  
Vol 23 (4) ◽  
pp. 620-622 ◽  
Author(s):  
Matthias Gorenflo ◽  
Hugo A. Katus ◽  
Raffi Bekeredjian
Keyword(s):  
Mitral Valve ◽  
Aortic Valve ◽  
Mitral Regurgitation ◽  
Clinical Improvement ◽  
Mitral Valve Repair ◽  
Aortic Valve Stenosis ◽  
Mitral Valve Regurgitation ◽  
Male Adolescent ◽  
Valve Regurgitation ◽  
Valve Repair

AbstractPercutaneous edge-to-edge mitral valve repair using the MitraClipTM has not been used in children. The patient in this reported case was a 15-year-old male adolescent who presented postnatally with severe aortic valve stenosis and dysplasia of the mitral valve. The boy underwent surgical valvuloplasty at the age of 3 months and an aortoventriculoplasty with three re-operations. At the age of 15 years, he developed severe mitral valve regurgitation. Owing to high surgical risks, a MitraClipTM was implanted with a reduction of mitral regurgitation from grade 4+ to 2+, translating into a rapid clinical improvement.

scholarly journals Percutaneous Mitral Valve Repair with the MitraClip System in the Current Clinical Practice

Hearts ◽  
2021 ◽  
Vol 2 (1) ◽  
pp. 74-86
Author(s):  
Sergio Sorrentino ◽  
Alessandra Berardini ◽  
Giovanni Statuto ◽  
Andrea Angeletti ◽  
Giulia Massaro ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Mitral Valve ◽  
Mitral Valve Repair ◽  
Randomized Clinical Trials ◽  
Treatment Options ◽  
Mitral Valve Regurgitation ◽  
Valve Repair ◽  
Percutaneous Mitral Valve Repair ◽  
Mitraclip System

Severe mitral valve regurgitation (MR) carries a significant burden both in prognosis and quality of life of patients, as well as on healthcare systems, with high rates of hospitalization for heart failure. While mitral valve surgery constitutes the first-line treatment option for primary MR in suitable patients, surgical treatment for secondary severe MR remains controversial, with a substantial lack of evidence on a survival benefit. In recent decades, percutaneous mitral valve repair has emerged as an alternative treatment for patients deemed not suitable for surgery. Among several devices under development or evaluation, the MitraClip system is the most widespread and is supported by the strongest evidence. While the role of MitraClip in patients with chronic primary MR who are not deemed suitable for surgery is well established, with consistent data showing improvement in both prognosis and quality of life, MitraClip treatment in secondary MR is a rapidly evolving field. Two recent randomized clinical trials generated apparently controversial results but actually provided an interesting pathophysiologic frame that could help discerning patients who will benefit from the procedure versus patients who will not. In this review, we will discuss current treatment options for mitral regurgitation, focusing on percutaneous mitral valve repair with the MitraClip system.

scholarly journals Percutaneous Interventions for Secondary Mitral Regurgitation

2020 ◽  
Vol 13 (8) ◽  
Author(s):  
Mahboob Ali ◽  
Satya S. Shreenivas ◽  
David N. Pratt ◽  
Donald R. Lynch ◽  
Dean J. Kereiakes
Keyword(s):  
Clinical Trials ◽  
Mitral Valve ◽  
Mitral Regurgitation ◽  
Mitral Valve Repair ◽  
Treatment Options ◽  
Left Ventricular ◽  
Ventricular Assist Devices ◽  
Functional Mitral Regurgitation ◽  
Left Ventricular Assist Devices ◽  
Valve Repair

Mitral regurgitation is frequently associated with ventricular dysfunction and carries a high mortality. Guideline-directed medical therapy, surgical mitral valve repair or replacement, and, in the setting of advanced heart failure, heart transplant and left ventricular assist devices have been the mainstay of treatment. However, rapid advancement in the field has resulted in approval of edge-to-edge mitral valve repair with the MitraClip, and there are several novel catheter-based percutaneous options in clinical trials. Percutaneous options, while promising, must be deployed in patients who are most likely to benefit, and thus, understanding the pathophysiology of specific subgroups of patients with functional mitral regurgitation (eg, disproportionate versus proportionate mitral regurgitation) is key to the success of new devices. We review the pathophysiology, percutaneous therapeutic treatment options, and ongoing clinical trials for functional mitral regurgitation.

Sign in / Sign up

Export Citation Format

Share Document